Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that Ortho-McNeil-Janssen Pharmaceuticals' Levaquin is the preferred quinolone antibiotic among more than half of all general medical-surgical hospitals in the United States. Quinolone antibiotics are used to treat lung, sinus, skin and urinary tract infections caused by numerous bacterial pathogens.

"Based on our October 2008 audit, intravenous Levaquin was stocked in more hospitals than both Bayer's intravenous Cipro and generic intravenous ciprofloxacin combined," stated Matthew W. Mahr, Pharm.D., M.B.A., analyst at AMR.

The newly released edition of the Quinolone Monthly Monitor (U.S.) also finds that over 70 percent of hospitals reported having a closed hospital formulary for antibiotics. Large hospitals were found to be most likely to have a closed formulary for antibiotics. These closed formularies create restrictions on what can be prescribed in the hospital making it more difficult for a prescriber to use that medication.

Why Pharmaceutical Companies Need this Information

The Quinolone Monthly Monitor (U.S.) enables pharmaceutical companies to monitor formulary, stocking and restriction status of selected quinolone antibiotics. This study also gives information about the Pharmacy and Therapeutics Committee's actions for quinolones, which drive formulary and restriction status for these products.

About The Quinolone Monthly Monitor (U.S.)

The Quinolone Monthly Monitor (U.S.) is the industry's most comprehensive market research study of the formulary status of quinolone antibiotics. This study has been conducted monthly since June 1992 by collecting data from 300 pharmacy directors from a group of demographically representative acute care hospitals within the country.

About AMR

AMR (http://www.amr-data.com/) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com/.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  Natalia Morales             Elizabeth Marshall   Decision Resources          Decision Resources, Inc.   781-296-2691                781-296-2563   nmorales@dresources.com     emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Arlington Medical Resources

Contact: Natalia Morales of Decision Resources, +1-781-296-2691,
nmorales@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Advair's Patient Share in Newly Diagnosed Asthma Patients is Declining

View Now